BridgeBio Oncology Therapeutics Inc.
BBOT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $35 | $27 | $21 | $20 |
| G&A Expenses | $14 | $3 | $3 | $2 |
| SG&A Expenses | $14 | $3 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $49 | $30 | $23 | $22 |
| Operating Income | -$49 | -$30 | -$23 | -$22 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $4 | $2 | $1 | $2 |
| Pre-Tax Income | -$45 | -$28 | -$22 | -$20 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$45 | -$28 | -$22 | -$20 |
| % Margin | – | – | – | – |
| EPS | -1.9 | 0.039 | -0.02 | 0.12 |
| % Growth | -4,959.3% | 295.5% | -116.7% | – |
| EPS Diluted | -1.9 | 0.039 | -0.02 | 0.12 |
| Weighted Avg Shares Out | 24 | 24 | 24 | 17 |
| Weighted Avg Shares Out Dil | 24 | 24 | 24 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $2 | $2 | $2 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$49 | -$30 | -$23 | -$22 |
| % Margin | – | – | – | – |